Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Demyelinating Autoimmune Diseases, CNS: later-stage trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Demyelinating Autoimmune Diseases, CNS: 2 US clinical trials tracked, none currently recruiting.
Demyelinating Autoimmune Diseases, CNS is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Dragonfly Research, running 1 of these trials.
Enrollment posture brief
Registry condition demyelinating-autoimmune-diseases-cns
OPEN 0 | RECR 0% | LATE 1 | EARLY 0 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Demyelinating Autoimmune Diseases, CNS has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Demyelinating Autoimmune Diseases, CNS on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Demyelinating Autoimmune Diseases, CNS is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab
Dragonfly Research
NCT04837651
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)
State University of New York at Buffalo
NCT00304291
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Demyelinating Autoimmune Diseases, CNS records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Demyelinating Autoimmune Diseases, CNS trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Demyelinating Autoimmune Diseases, CNS page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Demyelinating Autoimmune Diseases, CNS trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Dragonfly Research sponsors the most Demyelinating Autoimmune Diseases, CNS trials on record, review their full trial history before evaluating a specific study. See Dragonfly Research's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Demyelinating Autoimmune Diseases, CNS condition card totals 2 registered trials; most-linked intervention T-Detect COVID T-cell blood test; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.